Note: This article is a data reference compiled from publicly available Australian Government sources (AIHW, ABS). It is intended for general informational and research purposes. All figures are sourced from the primary references linked throughout. This article does not constitute medical advice.
Australia's obesity burden is one of the most significant and costly public health challenges the country faces. Two in three adults are now living with overweight or obesity, a figure that has climbed steadily since national surveys began in 1995 and sits well above comparable high-income nations. This reference compiles the most current available data from the Australian Institute of Health and Welfare (AIHW) and the Australian Bureau of Statistics (ABS), covering adult and childhood prevalence, demographic and geographic variation, economic costs, long-term trends, and the emerging influence of GLP-1 pharmacotherapy on population-level projections.
| Metric | Figure | Source |
|---|---|---|
| Adults overweight or obese | 66% (2022) | AIHW NHS 2022 |
| Adults with obesity (BMI ≥30) | 32% (2022) | AIHW NHS 2022 |
| Adults overweight but not obese | 34% (2022) | AIHW NHS 2022 |
| Children aged 2–17 overweight or obese | 26% (2022) | AIHW NHS 2022 |
| Adults overweight or obese in 1995 | 57% | AIHW trend data |
| Adults with obesity in 1995 | 19% | AIHW trend data |
| Estimated economic cost | $11.8B (2017–18) | AIHW |
| Outer regional/remote adults overweight or obese | 70% (2022) | AIHW NHS 2022 |
The 2022 ABS National Health Survey (NHS), the most recent nationally representative measured dataset, found that 66% of Australian adults aged 18 and over were living with overweight or obesity. This breaks down as:
The figure has remained broadly stable since 2017–18 (67%), though the long-run trend since 1995 shows a marked rise, see the trends section below.
Obesity prevalence differed by sex in the 2022 NHS data:
Among young adults aged 18–24, obesity prevalence was 15% in men and 16% in women. By ages 65–74, this rose to 41% in men and 37% in women, a near-tripling across the lifespan, reflecting the cumulative nature of weight gain associated with ageing, reduced metabolic rate, and lifestyle changes.
Obesity becomes progressively more prevalent with age:
This gradient has consistent implications for chronic disease burden: cardiovascular disease, type 2 diabetes, sleep apnoea, osteoarthritis, and certain cancers all track closely with BMI and abdominal adiposity, and all increase in incidence with age.
One in four Australian children and adolescents (aged 2–17), 26%, were living with overweight or obesity in 2022, according to AIHW data. This proportion has remained stable since 2017–18, suggesting the upward trajectory seen in previous decades has plateaued, though not reversed.
Key sub-group findings:
The socioeconomic and Indigenous health equity gaps in childhood obesity are well documented in AIHW's dedicated childhood obesity report and are considered priority areas in the National Preventive Health Strategy.
Geography is among the strongest predictors of obesity prevalence in Australian adults. After adjusting for age, the 2022 NHS data shows:
| Remoteness Category | Adults Overweight or Obese |
|---|---|
| Major cities | 64% |
| Inner regional | 68% |
| Outer regional and remote | 70% |
The gap between major cities and outer regional/remote areas (6 percentage points) reflects structural barriers: reduced access to fresh food, fewer recreational facilities, greater reliance on motorised transport, and higher rates of socioeconomic disadvantage.
Within-state variation is substantial. Among PHN areas:
This 33 percentage point range between PHN areas illustrates that population-level averages obscure significant local variation. Rural and remote communities carry a disproportionately high burden, yet have the least access to specialist weight management services, dietitians, and, most recently, GLP-1 prescribers with appropriate obesity medicine training.
Australia has tracked overweight and obesity prevalence through nationally representative surveys since the mid-1990s. Age-standardised trend data from AIHW shows a clear and sustained increase over nearly three decades:
| Year | Overweight or Obese | Obesity Only |
|---|---|---|
| 1995 | 57% | 19% |
| 2007–08 | 61% | 25% |
| 2011–12 | 63% | 28% |
| 2017–18 | 67% | 31% |
| 2022 | 65% | 32% |
The slight dip in the combined overweight-or-obese figure between 2017–18 and 2022 reflects a modest decline in the overweight-but-not-obese category (from 36% to 34%), while obesity itself continued to rise incrementally (31% to 32%). The data does not suggest a reversal of the obesity trend, rather, some people previously classified as overweight have crossed into the obese category.
Over the full period, the proportion of adults with obesity has grown from 19% to 32%, a 68% relative increase across 27 years.
AIHW estimated that overweight and obesity cost the Australian economy approximately $11.8 billion in total costs in 2017–18. This figure encompasses direct healthcare expenditure (hospital admissions, GP visits, medications, specialist care) plus indirect costs (productivity losses, carer burden, and premature mortality).
More recent modelling, including analysis widely cited in policy discussions, projected Australia's total obesity-related economic cost at approximately AUD $39 billion (approximately 1.9% of GDP) as of 2019, with projections suggesting this could rise substantially through the 2030s if trends continue unchanged.
The AIHW Australian Burden of Disease framework (which measures years of healthy life lost to illness, disability, and premature death) identifies overweight and obesity as one of the leading attributable risk factors for chronic disease in Australia. The conditions most strongly linked to excess adiposity include:
For a detailed breakdown of how excess adiposity drives metabolic dysfunction at the tissue level, see our guide to visceral fat and metabolic risk.
The 26% prevalence of overweight or obesity among Australian children aged 2–17 is not simply a paediatric health issue, it has direct consequences for adult disease burden. AIHW's birth cohort analysis of overweight and obesity trajectories demonstrates strong tracking: children with obesity are significantly more likely to carry excess weight into adulthood, and to develop associated cardiometabolic conditions earlier.
The socioeconomic gradient is pronounced: children from the lowest socioeconomic areas were more than twice as likely to be living with obesity as those in the highest areas (11% vs 4.4%, AIHW 2017–18). This gap compounds across generations and underlies Australia's persistent health equity disparities.
The emergence of GLP-1 receptor agonist medications (semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro)) represents the first pharmacological intervention with clinically meaningful effect sizes on obesity at scale. Clinical trials demonstrate average body weight reductions of 10–15% with semaglutide and 15–21% with tirzepatide, substantially exceeding prior pharmacotherapy.
Australia's PBAC recommendation to list Wegovy (November 2025) signalled a coming shift in treatment access, though eligibility criteria (BMI ≥30, or ≥27 with comorbidities), the recommendation not yet being in effect, and prescriber capacity constraints mean population-level impact will take years to materialise. For more on which medications are currently subsidised and eligible criteria, see PBS weight loss medications in Australia.
Global modelling does not yet support confident projections that GLP-1 availability alone will reverse Australia's obesity prevalence trajectory. The 2026 WHO global obesity guidelines acknowledge GLP-1 agonists as a complementary tool within a broader system-level response, explicitly noting that medication-only approaches without structural food environment and physical activity policy changes are unlikely to achieve population-level reversal.
To understand the biological mechanisms behind why these medications work, see how GLP-1 agonists work.
Key factors constraining population-level impact in Australia:
Most Australian national obesity statistics rely on self-reported or measured BMI from the ABS National Health Survey. Key limitations include:
Australia's obesity burden in 2026 is characterised by:
Emerging research on GLP-1 receptor agonists and alcohol cravings: 2025 RCT data, the reward-pathway mechanism, and what it means for semaglutide users.
Comparing bariatric surgery and GLP-1 medications on efficacy, durability, cost, and risk in Australia today, plus a practical decision framework for 2026.
The SELECT trial showed semaglutide cut MACE by 20% in non-diabetic patients with obesity and CV disease. Mechanisms, findings, and Australian PBS access.